Seegene seeks wider adoption of real-time PCR

By Joseph James Whitworth contact

- Last updated on GMT

©iStock/nikesidoroff
©iStock/nikesidoroff
Seegene is developing second-generation real-time PCR technology which it has patented in the US and Europe.

The firm said it is the only analysis method capable of providing and analyzing multi-Ct (threshold cycle) values in a single detection channel, which offers simultaneous amplification of multiple genes and real-time quantitative analysis.

Seegene's Universal SG Fluorescence-labeled oligo allows detection of any analyte with a single oligo. This is applied to Seegene’s Allplex range and products being developed with partners.

The firm said second-generation real-time PCR technology will reduce development time of multiplex assays from more than a year to several weeks.

Seegene said current molecular diagnostic (MDx) products are limited due to approaches that can detect only one target per channel.

Conventional technologies require fluorescence-labeled oligos to be specifically designed for each target DNA, which is time-consuming and costly for development, added the company.

Jong-Yoon Chun, CEO of Seegene, said the second-generation real-time PCR is the core technology that will enable the wide use of multiplex MDx and automated assay development.

“It will enable our business to expand into new areas, such as detections of pathogens in animals and plants, food safety and quarantine inspections.”

Related news

Show more

Related products

Related suppliers